TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06639451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RANGER™ Paclitaxel Coated Balloon Catheter
Description: A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon coated with paclitaxel at the end of it. When the tube is in place, it inflates to open the blood vessel, so that normal blood flow is restored. The tube is then removed.
Study: NCT06577025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Cilta-cel infusion will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D and Tec-D consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D and Tec-D consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously as a part of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously as a part of induction.
Study: NCT06684730

Intervention type: PROCEDURE
Intervention: Kinematic Analysis
Description: Kinematic analysis of shoulder abduction, elbow flexion, and cervical flexion will be performed during simulated tasks of drinking water from a glass and filling glass of water.

Intervention type: PROCEDURE
Intervention: Kinematic Analysis
Description: Kinematic analysis of shoulder abduction, elbow flexion, and cervical flexion will be performed during simulated tasks of drinking water from a glass and filling glass of water.

Intervention type: PROCEDURE
Intervention: Parkour Completion Time
Description: A 10-item daily living activities parkour will be prepared for the participants. During the parkour, the participant will be given the following tasks: opening and closing 10 jar lids, slicing a 20cm cylindrical dough into 10 pieces, simulating drinking soup from a bowl 15 times with a spoon (standard bowl 150 ml, standard tablespoon 10 ml), simulating eating meatballs from a plate with a fork 10 times (approximately 6-10 meatballs per serving), simulating pouring water from a pitcher into a glass 10 times, simulating drinking water from a glass 10 times, simulating brushing teeth for 2 minutes, opening 10 clothespins attached to the edge of a cardboard box and attaching them to the other side, simulating opening and closing a zipper, and putting on shoes and tying shoelaces. The course completion time will be recorded.

Intervention type: PROCEDURE
Intervention: Parkour Completion Time
Description: A 10-item daily living activities parkour will be prepared for the participants. During the parkour, the participant will be given the following tasks: opening and closing 10 jar lids, slicing a 20cm cylindrical dough into 10 pieces, simulating drinking soup from a bowl 15 times with a spoon (standard bowl 150 ml, standard tablespoon 10 ml), simulating eating meatballs from a plate with a fork 10 times (approximately 6-10 meatballs per serving), simulating pouring water from a pitcher into a glass 10 times, simulating drinking water from a glass 10 times, simulating brushing teeth for 2 minutes, opening 10 clothespins attached to the edge of a cardboard box and attaching them to the other side, simulating opening and closing a zipper, and putting on shoes and tying shoelaces. The course completion time will be recorded.

Intervention type: PROCEDURE
Intervention: Fatigue Scale
Description: A pre- and post-parkour will be employed, including a 5-point Likert scale for fatigue assesment, hand function assessment scales and kinematic analysis to participants. The results before and after the parkour will be compared.

Intervention type: PROCEDURE
Intervention: Fatigue Scale
Description: A pre- and post-parkour will be employed, including a 5-point Likert scale for fatigue assesment, hand function assessment scales and kinematic analysis to participants. The results before and after the parkour will be compared.
Study: NCT06684171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiographic guidance
Description: After detailed evaluation, patients randomized in this group will undergo TEER procedure under guidance of fully echocardiography but any fluoroscopy in the entire process.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic guidance
Description: After detailed evaluation, patients randomized in this group will undergo TEER procedure under combined guidance of echocardiography and fluoroscopy in the entire process.
Study: NCT06685705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate and Bupivacaine 0.125%
Description: patients will receive 15 mg of 0.5% hyperbaric bupivacaine + 50 mg Magnesium sulfate intrathecally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and Neostigmine
Description: patients will receive 15mg of 0.5% hyperbaric bupivacaine + 50 µg Neostigmine intrathecally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl and bupivacaine
Description: patients will receive 15mg of 0.5% hyperbaric bupivacaine + 25µg of fentanyl intrathecally.
Study: NCT06619496

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human-led fall prevention program
Description: Human-led evidence-based fall prevention programs include Matter of Balance, Tai Chi Moving for Better Balance, Walk with Ease, or Arthritis Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-led fall prevention program
Description: The avatar-led fall prevention program consists of the Otago Exercise Program
Study: NCT06624007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pediatric Nursing Excellence (PNE) model
Description: The intervention group will apply pediatric Nursing Excellence (PNE) model included 28 Likert-type questions to assess nurses' general excellence level regarding the care of children undergoing orthopedic surgeries grouped under five main categories including engagement, values, principles, care delivery and continuous improvement.
Study: NCT06682013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual agent
Description: The virtual agent is an interactive audio agent that is similar to voice agents that interact with callers in many industries today. They create a very human-like interaction in contrast to more traditional virtual call agents that can only respond to menu options (e.g. choose 1 for appointments, choose 2 for questions about your bill, etc.). The virtual agent is engineered to accomplish the very specific task of onboarding the patient on use of the RPM devices. It is trained to understand normal human English speech, detects emotional tone and frustration of callers, and is trained to deescalate when appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Human agent
Description: The human agent will onboard the patient on use of the RPM devices.
Study: NCT06684938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacroiliac injection
Description: sacroiliac injection with local anaesthetic and corticosteroids
Study: NCT05730582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parkland Diabetes Detection Program (PDDP) Screening Invitation
Description: The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parkland Diabetes Detection Program (PDDP) Screening Invitation
Description: The PDDP is designed to supplement and close screening gaps that persist despite opportunistic screening. Program staff order diabetes screening tests for randomized patients, then mail screening invitation letters to inform patients that they are at risk for diabetes. The letter informs them that a screening test has been ordered, and requests that they complete testing at their clinic lab. Patients who were mailed the letter but have not completed screening after 30 days are tracked and are send a second reminder invitation. Patients randomized to the targeted-tailored intervention study arm receive an additional phone call after 30 days.
Study: NCT05102474

Intervention type: OTHER
Intervention: Polysomnography (PSG)
Description: PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.

Intervention type: OTHER
Intervention: Polysomnography (PSG)
Description: PSG is the gold standard for objectively measuring sleep in the laboratory setting. The procedure consists of electrodes measuring brain activity (electroencephalography, EEG), eye movements (electrooculography, EOG), muscle activity (electromyography, EMG), respiratory events, snoring activity, blood oxygen saturation, and body position. Video surveillance during the sleep study can also monitor for itching events that occur during the night.
Study: NCT05711186

Intervention type: OTHER
Group type: OTHER
Intervention: Structured SDM
Description: The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure.
Study: NCT05903053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Self-Regulation Intervention
Description: Participants enrolled in a separate protocol (UC Davis IRB ID#1077801) will be invited to participate upon meeting eligibility criteria. All participants will receive the intake and exit assessment battery, with the intake assessment battery being completed as part of IRBNet ID#1077801. A multiple baseline design across participants will be used with varying introduction of treatment elements for a subset of enrolled intervention participants. An intense intervention phase will follow the baseline phase in which 45-60 minute intervention sessions will occur two times per week for approximately 4-6 weeks for a total of 8 sessions. At the conclusion of the intense intervention phase, coaches will provide booster sessions once weekly for a month (4 sessions total).
Study: NCT06577025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally as a part of induction.
Study: NCT06366516

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Methylation Test
Description: Participants who aged 25-65 years with high-risk HPV infection are recruited.To start with,cervical exfoliated cells are collected, coded (according to the actual enrollment sequence), and stored in the pathology department where methylation testing is performed.In addition,patients will underwent colposcopy and biopsy.~Patients are followed up by cytology, high-risk HPV and methylation tests at 6 and 12 months after enrollment.Cervical conization and hysterectomy will be taken if necessary according to histopathological results. The clinical endpoint is reached when CIN2+ is confirmed by histopathological result.
Study: NCT05969119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive either 60 mg oral Pyridostigmine every 6 hours or Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Study: NCT06233916

Intervention type: DRUG
Group type: OTHER
Intervention: [14C] D-1553
Description: \[14C\] D-1553 (approximately 400 mg/80 μCi)
Study: NCT05969119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parturients with postoperative Postdural puncture headache and a Visual analogue scale (VAS score) of ≥5 will receive Placebo tablets similar in shape to pyridostigmine tablets every 6 hours.
Study: NCT06577025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally as a part of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally as a part of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally as a part of induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously as a part of conditioning regimen.
Study: NCT05381077

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Whole body MRI (ZTE sequence)
Study: NCT05737797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical cytology during surgery.
Description: Cervical cytology will be performed by the surgeon in the operating theatre before hysterectomy.
Study: NCT05964270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: e-coach multipel myeloma (MM)
Description: In this study we developed a multimodal patient-centered MM e-coach between September 2019 and June 2020. The content of the intervention consist of eight modules and was tested in a pilot study between June 2020 and August 2020 (F-ITUMM) 22. The e-coach is digitally managed, following three phases of the tiers of VBHC as presented in Figure 1. The tiers are classified in health status, process of recovery and sustainability of health 30. Furthermore, all medication information plus current dose and frequency per unit time are integrated in the e-coach. Reminders are sent if a session or a medication unit time is exceeded. Feasibility was tested for patients as well as healthcare professionals. The F-ITUMM trial concluded that the MM e-coach has the potential to support both recently diagnosed MM patients and healthcare professionals during MM treatment, and is a promising application to improve adherence .
Study: NCT05794061

Intervention type: BEHAVIORAL
Intervention: Neuropsychological instruments
Description: Cognitive and behavioral tests and questionnaires

Intervention type: BEHAVIORAL
Intervention: Neuropsychological instruments
Description: Cognitive and behavioral tests and questionnaires
Study: NCT06577025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered intravenously as a part of conditioning regimen.
Study: NCT06555796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluritamig
Description: IV infusion
Study: NCT05991115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital to Home Transition (H2H)
Description: The intervention for this study is a multi-component navigation-supported intervention for children hospitalized with asthma. Navigators will work with families for 12-months post-discharge. Trained asthma educator/navigators will work to address challenges with asthma care after discharge; will include maximum 15 contacts/12 months. The asthma navigators within this study will attempt to maintain direct contact with participants primary care doctors through email, fax, and/or postal mail as means for delivering asthma action plans, prescription updates, and patient appointment scheduling. The asthma navigators for intervention participants will attempt to maintain contact with the school nurse in efforts to have a line of communication with the school. Asthma navigators will assist families in all home-based needs pertaining to their child's asthma.
Study: NCT05702034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milvexian
Description: Milvexian will be administered orally.
Study: NCT05001087

Intervention type: OTHER
Intervention: Observation
Description: Not applicable-Observational study
Study: NCT05702034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study: NCT06408935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered IV and SC.
Study: NCT06630286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL/LEN
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISL/LEN
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM B/F/TAF
Description: Tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM ISL/LEN
Description: Tablet administered orally
Study: NCT05987735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BLAME-LESS
Description: The BLAME-LESS program was designed to educate about common defense responses that may occur during and after (sexual) violence. The main goal of the program is to reduce the feelings of shame and/or guilt related to these responses. The program was created in collaboration with licensed developmental and clinical psychologists with extensive psycho-trauma expertise, young adults who are experienced experts, visual artists, and web designers. The program is offered via a website and consists of three modules.
Study: NCT05843643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT05528458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80Mg Tab
Description: Subjects have a osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection
Study: NCT05295771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival Phenotype Modification
Description: Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival Phenotype Modification
Description: Autogenous Connective Tissue Graft is the current gold standard for soft tissue phenotype modification. This is being compared with a substitute material called Geistlich Fibro-Gide ® for soft tissue phenotype modification before orthodontic treatment. Geistlich Fibro-Gide ® is a porcine, porous, resorbable and volume-stable collagen matrix, designed for soft-tissue regeneration. Surgical flap design will be an envelope for both interventions.
Study: NCT03712657

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: 1. preoperative pain control;~2. avoiding application of ureter;~3. avoiding application of gastric tube;~4. avoiding application of irrigation;~5. avoiding application of drainage;~6. early exercising postoperatively;~7. early oral feeding postoperatively;~8. early discharging.
Study: NCT05665075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QN-023a
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: Lympho-conditioning Agent
Study: NCT04912440

Intervention type: DEVICE
Intervention: MSE-ERCP
Description: No interventional study, MSE-ERCP performed within routine treatment, (approved indication of device)
Study: NCT04709692

Intervention type: DRUG
Group type: OTHER
Intervention: (+)-SJ000557733 (SJ733)
Description: Anti-Malarial

Intervention type: DRUG
Group type: OTHER
Intervention: (+)-SJ000557733 (SJ733)
Description: Anti-Malarial

Intervention type: DRUG
Group type: OTHER
Intervention: (+)-SJ000557733 (SJ733)
Description: Anti-Malarial
Study: NCT06486597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Liquid meal
Study: NCT04774575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biomarker-guided strategy
Description: Patients will follow a biomarker-guided strategy based on specific non-invasive biomarkers as defined in EUTRAIN-1 study on the basis of its detection and prediction capacities for rejection at M3 to decide whether a biopsy is performed. At M12 a routine biopsy is performed